Englander Institute for Precision Medicine

Publications

Found 851 results
Author Title Type [ Year(Asc)]
2024
Naulin F, Guilbaud E, Galluzzi L.  2024.  PARP7 and nucleic acid-driven oncosuppression.. Cell Mol Immunol.
Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B et al..  2024.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. Cancer Lett. 584:216608.
Wu Y, Foollee A, Chan AY, Hille S, Hauke J, Challis MP, Johnson JL, Yaron TM, Mynard V, Aung OH et al..  2024.  Phosphoproteomics-directed manipulation reveals SEC22B as a hepatocellular signaling node governing metabolic actions of glucagon.. Nat Commun. 15(1):8390.
Glass J, Elemento O.  2024.  The power and perils of large language models in haematology.. Br J Haematol.
San Pedro JManuel Bra, Aranda F, Buqué A, Galluzzi L.  2024.  Preface.. Methods Cell Biol. 185:xvii-xxiv.
Sun BB, Suhre K, Gibson BW.  2024.  Promises and challenges of populational proteomics in health and disease.. Mol Cell Proteomics. :100786.
Sinha NK, McKenney C, Yeow ZY, Li JJ, Nam KHong, Yaron-Barir TM, Johnson JL, Huntsman EM, Cantley LC, Ordureau A et al..  2024.  The ribotoxic stress response drives UV-mediated cell death.. Cell.
Vong KIoi, Lee S, Au KSing, T Crowley B, Capra V, Martino J, Haller M, Araújo C, Machado HR, George R et al..  2024.  Risk of meningomyelocele mediated by the common 22q11.2 deletion.. Science. 384(6695):584-590.
Halama A, Zaghlool S, Thareja G, Kader S, Muftah WAl, Mook-Kanamori M, Sarwath H, Mohamoud YAli, Stephan N, Ameling S et al..  2024.  A roadmap to the molecular human linking multiomics with population traits and diabetes subtypes.. Nat Commun. 15(1):7111.
Nanaware PP, Khan ZN, Clement CC, Shetty M, Mota I, Seltzer ES, Dzieciatkowska M, Gamboni F, D'Alessandro A, Ng C et al..  2024.  Role of the afferent lymph as an immunological conduit to analyze tissue antigenic and inflammatory load.. Cell Rep. 43(6):114311.
Schweickart A, Batra R, Neth BJ, Martino C, Shenhav L, Zhang AR, Shi P, Karu N, Huynh K, Meikle PJ et al..  2024.  Serum and CSF metabolomics analysis shows Mediterranean Ketogenic Diet mitigates risk factors of Alzheimer's disease.. NPJ Metab Health Dis. 2(1):15.
Altorki NK, Bhinder B, Borczuk AC, Elemento O, Mittal V, McGraw TE.  2024.  A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer.. Cell Rep Med. :101438.
Sundaram L, Kumar A, Zatzman M, Salcedo A, Ravindra N, Shams S, Louie BH, S Bagdatli T, Myers MA, Sarmashghi S et al..  2024.  Single-cell chromatin accessibility reveals malignant regulatory programs in primary human cancers.. Science. 385(6713):eadk9217.
Cullati SN, Akizuki K, Chen J-S, Johnson JL, Yaron-Barir TM, Cantley LC, Gould KL.  2024.  Substrate displacement of CK1 C-termini regulates kinase specificity.. Sci Adv. 10(19):eadj5185.
Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, Drozenova J, Mojzisova K, Fialova A, Vosahlikova S et al..  2024.  Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.. Nat Commun. 15(1):2528.
Breves SL, Di Giammartino DCampigli, Nicholson J, Cirigliano S, Mahmood SRaza, Lee UJin, Martinez-Fundichely A, Jungverdorben J, Singhania R, Rajkumar S et al..  2024.  Three-dimensional regulatory hubs support oncogenic programs in glioblastoma.. bioRxiv.
Min D, Fiedler J, Anandasabapathy N.  2024.  Tissue-resident memory cells in antitumoral immunity and cancer immunotherapy.. Curr Opin Immunol. 91:102499.
Shah Y, Yang H, Mueller FB, Li C, Rahim SEGul, Varma E, Salinas T, Dadhania DM, Salvatore SP, Seshan SV et al..  2024.  Transcriptomic signatures of chronic active antibody-mediated rejection deciphered by RNA sequencing of human kidney allografts.. Kidney Int. 105(2):347-363.
Sternberg CN, Freedland SJ, George DJ, Morgans AK.  2024.  Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale.. Clin Genitourin Cancer. 22(6):102171.
Markowski MC, Sternberg CN, Wang H, Wang T, Linville L, Marshall CH, Sullivan R, King S, Lotan TL, Antonarakis ES.  2024.  TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.. Oncologist.
Newman LA, Chen Y, Martini R, Demaria S, Formenti S, Elemento O, Davis MB.  2024.  Tumor-Associated Lymphocytes and Breast Cancer Survival in Black and White Women.. JAMA Surg.
Holicek P, Guilbaud E, Klapp V, Truxova I, Spisek R, Galluzzi L, Fucikova J.  2024.  Type I interferon and cancer.. Immunol Rev. 321(1):115-127.
Reduzzi C, Nicolo' E, Singhal S, Venetis K, Ortega-Franco A, de Miguel-Perez D, Dipasquale A, Gouda MA, Saldanha EF, Kasi PM et al..  2024.  Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors.. Crit Rev Oncol Hematol. 203:104483.
Hsu J, Kim S, Anandasabapathy N.  2024.  Vaccinia Virus: Mechanisms Supporting Immune Evasion and Successful Long-Term Protective Immunity.. Viruses. 16(6)
Bensoussan Y, Elemento O, Rameau A.  2024.  Voice as an AI Biomarker of Health-Introducing Audiomics.. JAMA Otolaryngol Head Neck Surg.